论文部分内容阅读
目的:检测NOK蛋白在非小细胞肺癌中的表达,分析其表达率与病理分型、分级及临床TNM分期间的关系,为研究NOK的功能及其机制提供临床证据。方法:采用免疫组织化学EnVinsion法检测NOK蛋白在非小细胞肺癌(NSCLC)中的表达。结果:免疫组化结果显示NOK阳性表达主要位于胞质中。NSCLC中NOK总阳性率68.1%,癌旁组织阳性率只有12.1%,差异性非常显著(P=0.000);肺鳞癌和腺癌总阳性率分别为60.49%、78.33%,两者差异显著(P=0.009);鳞癌中分化、低分化阳性率分别为51.1%、72.22%,差异显著(P=0.01),腺癌的高、中、低分级的阳性率分别是20.0%、79.5%、100%,经Kruskal-WallisH检验差异性非常显著(P=0.001);NSCLC(鳞癌、腺癌)TNM分期Ⅱa、Ⅱb、Ⅲa、Ⅲb的阳性率,经Kruskal-WallisH检验其差异性非常显著(P=0.000)。结论:NOK在肺鳞癌、腺癌中高表达,表达的高低与病理分型、分级及临床TNM分期(转移)有关。
OBJECTIVE: To detect the expression of NOK protein in non-small cell lung cancer (NSCLC) and to analyze the relationship between its expression rate and pathological classification, grading and TNM clinical stage, so as to provide clinical evidence for studying the function and mechanism of NOK. Methods: The expression of NOK protein in non-small cell lung cancer (NSCLC) was detected by immunohistochemistry EnVionion method. Results: Immunohistochemistry showed that the positive expression of NOK was mainly located in the cytoplasm. The positive rate of NOK in NSCLC was 68.1% and the positive rate of paracancerous tissue was only 12.1% (P = 0.000). The total positive rates of lung squamous cell carcinoma and adenocarcinoma were 60.49% and 78.33%, respectively P = 0.009). The positive rate of differentiated and poorly differentiated squamous cell carcinoma was 51.1% and 72.22%, respectively (P = 0.01). The positive rate of adenocarcinoma was 20.0%, 79.5% 100%. The Kruskal-Wallis H test showed significant difference (P = 0.001). The positive rates of TNM stage Ⅱa, Ⅱb, Ⅲa and Ⅲb in NSCLC were significantly different P = 0.000). Conclusion: NOK is highly expressed in lung squamous cell carcinoma and adenocarcinoma. The expression of NOK is related to the pathological classification, grading and clinical TNM stage (metastasis).